Ginkgo Bioworks (DNA) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on June 11, 2026, with shareholders able to vote online, by phone, or by mail.

• Shareholders will vote on electing six directors, ratifying Deloitte & Touche LLP as auditor, and an advisory say-on-pay for executive compensation.

• The proxy statement details voting procedures, record dates, and encourages electronic participation and advance voting.

• Forward-looking statements are included, with risks highlighted in the company's SEC filings.

Voting matters and shareholder proposals

• Six director nominees are up for election, with two elected by Class B shareholders and four by both Class A and B shareholders.

• Ratification of Deloitte & Touche LLP as independent auditor for fiscal year 2026 is proposed.

• Advisory vote on executive compensation is included.

• Shareholders may submit proposals for the 2027 meeting, with deadlines and requirements specified.

Board of directors and corporate governance

• The board will reduce from seven to six members after the meeting.

• Director nominees bring a mix of long and short tenures, with a focus on diversity and relevant expertise.

• Board committees (Audit, Compensation, Nominating & Corporate Governance) are composed entirely of independent directors.

• The board maintains an independent chair structure and regularly reviews its leadership approach.

• Shareholder engagement is emphasized, including direct communication channels and employee ownership.